Search
Search Results
-
Trastuzumab for Active Targeting in Cancer Therapy
With the advent of targeted therapies came a new paradigm for cancer treatment. The specific interaction between ligands and surface receptors has...
-
Engineering Nanobody Targeting Cancer Stem Cells
Nanobodies (Nbs) are great molecular tools that can circumvent the limitations of traditional antibodies such as large size, low stability, slow...
-
Targeting the Epigenetic Landscape for Cancer Therapy
The role of epigenetics, focusing on changes in gene functions unrelated to DNA sequence, is becoming increasingly evident in cancer initiation,...
-
Nanomedicine Targeting Cancer Stem Cells
Cancer stem cells (CSCs) constitute a subset of cells endowed with the remarkable abilities of self-renewal, proliferation, and differentiation....
-
Recent Advances in FDA-Approved Kinase Inhibitors Targeting Lung Cancer
Lung cancer is a chronic deadly disease and is implicated with highest mortality rate among all cancers since years. Kinase are the...
-
Targeting KRAS in cancer
RAS family variants—most of which involve KRAS —are the most commonly occurring hotspot mutations in human cancers and are associated with a poor...
-
Novel Therapeutics Targeting Cancer Stem Cell Surface Markers
Cancer stem cells (CSCs) are a subpopulation of undifferentiated cells possessing the ability of self-renewal and differentiation into non-CSCs...
-
Recent Advances in FDA-Approved Kinase Inhibitors Targeting Lung Cancer
Lung cancer is a chronic deadly disease and is implicated with highest mortality rate among all cancers since years. Kinase are the...
-
Targeting Toll-Like Receptors in Cancer Immunotherapy
Recently, novel cancer immunotherapy approaches have gained rising interest. While chronic inflammation has been defined as a major hallmark of...
-
Targeting ROS in cancer: rationale and strategies
Reactive oxygen species (ROS) in biological systems are transient but essential molecules that are generated and eliminated by a complex set of...
-
Epi-Drugs Targeting RNA Dynamics in Cancer
From the early discovery of ribonucleic acid in 1868, the RNA world has seen constant evolution. To date, more than ten types of RNA species are...
-
Emerging Trends in Monoclonal Antibody Therapies Targeting Cancer
Monoclonal antibody-based immunotherapy is a crucial component of cancer therapy. Advances in genetic engineering allowed for modifications that have...
-
Review immune response of targeting CD39 in cancer
The ATP-adenosine pathway has emerged as a promising target for cancer therapy, but challenges remain in achieving effective tumor control. Early...
-
Ligand-based active targeting strategies for cancer theranostics
In the past decades, for the intermediate or advanced cancerous stages, preclinical and clinical applications of nanomedicines in cancer theranostics...
-
Personalized Cancer Vaccines Targeting Neoantigens
Cancer vaccine therapies targeting tumor-associated antigens have been extensively studied as immunotherapies that elicit antitumor immunity, but the...
-
New Developments in Targeting Cancer Cachexia
Within the cancer population, 50–80% of patients will develop cachexia, impacting negatively on their ability to tolerate or gain benefit from either...
-
Therapeutics Targeting Cancer Stem Cell Signalling Pathways
Cancer stem cells (CSCs) are a small population of G0-arrested tumor cells. They contribute to the metastasis, recurrence, and heterogeneity of...
-
Targeting and engineering long non-coding RNAs for cancer therapy
RNA therapeutics (RNATx) aim to treat diseases, including cancer, by targeting or employing RNA molecules for therapeutic purposes. Amongst the most...
-
Ligand-based adoptive T cell targeting CA125 in ovarian cancer
BackgroundOvarian cancer (OC) is a highly aggressive gynecological malignancy prevalent worldwide. Most OC cases are typically diagnosed at advanced...
-
Progress in Targeting KRAS Directly
RAS research has entered the world of translational and clinical science. Progress has been based on our appreciation of the role of RAS mutations in...